Pharmaceutical companies are in a race to debut strong cholesterol-reducing drugs specifically targeted to those who don't respond to traditional medications, cardiologists and researchers said this week.
The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.
